A 12-week recovery cycle typically structures weeks 1–6 as a loading phase with higher-frequency administration, weeks 7–10 as a consolidation phase at reduced frequency, and weeks 11–12 as a taper. The specific peptide determines whether loading makes pharmacological sense — not all peptides have a loading rationale.
Which peptides actually warrant a loading phase?
Loading makes sense for peptides where tissue saturation is the proposed mechanism — TB-500 is the clearest example, where actin-sequestering effects are theorised to require sustained elevated levels before the cell migration benefit is fully expressed. BPC-157, whose effects appear more immediate via signalling pathways, has less pharmacological justification for formal loading, though many protocols still use it. GH secretagogues do not load in the same way — their pulse-dependent mechanism means frequency matters more than cumulative dose.
Why taper at the end of a cycle?
Tapering is not pharmacologically required for any peptide with a short half-life — BPC-157 and TB-500 both clear quickly and do not suppress endogenous systems in the way anabolic steroids do. The taper convention in peptide cycling is largely borrowed from other compound protocols and serves more as a psychological transition than a physiological necessity. That said, reducing frequency in the final weeks while assessing how the injury or condition is responding is sensible protocol management regardless of the pharmacological necessity.